Rigel Pharmaceuticals | RIGL - Ebit

Stock Price
29.64
Daily Change
0.01 0.03%
Monthly
-13.21%
Yearly
50.46%
Q1 Forecast
33.68

Rigel Pharmaceuticals reported $447K in EBIT for its fiscal quarter ending in June of 2024.





Ebit Change Date
Agenus USD -13.31M 19.08M Mar/2025
Amgen USD 3.96B 464M Dec/2025
Anika Therapeutics USD -4.28M 3.58M Mar/2025
Arrowhead Research USD 40.81M 17.01M Dec/2025
AstraZeneca USD 2.97B 4.48B Dec/2025
BioMarin Pharmaceutical USD 198.39M 230.08M Dec/2025
Bristol-Myers Squibb USD 3.47B 567M Dec/2025
Celldex Therapeutics USD -87.15M 13.54M Dec/2025
Daiichi Sankyo JPY 89.54B 42.01B Dec/2025
Eli Lilly USD 8.99B 1.57B Dec/2025
Halozyme Therapeutics USD -88.41M 306.33M Dec/2025
Heron Therapeutics USD -4.46M 5.76M Sep/2024
Intrexon USD -26.3M 2.91M Jun/2024
Ionis Pharmaceuticals USD -215M 54.82M Dec/2025
Karyopharm Therapeutics USD -26.28M 1.84M Sep/2024
Ligand Pharmaceuticals USD 158.89M 115.32M Sep/2025
MacroGenics USD 20.16M 55.51M Sep/2025
Neurocrine Biosciences USD 227.9M 11.4M Dec/2025
Pfizer USD 4.65B 71M Dec/2025
Regeneron Pharmaceuticals USD 898.6M 211.3M Dec/2025
Rigel Pharmaceuticals USD 447K 1.52M Jun/2024
Ultragenyx Pharmaceutical USD -114M 56.89M Dec/2025
Veracyte USD 24.63M 1.52M Dec/2025